Although the involvement of FOXO4 has been investigated in tumor development as a downstream target of the PTEN/PI3K/AKT signaling pathway, few reports have discussed FOXO4 expression in HCC and its association with survival, prognosis, and drug resistance in patients with cancer. The gene discussed is FOXO4; the disease is hepatocellular carcinoma.